Cargando…

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial

BACKGROUND: LUX-Lung 8 was a randomised, controlled, phase 3 study comparing afatinib and erlotinib as second-line treatment of patients with advanced squamous cell carcinoma (SCC) of the lung. We report the final overall survival (OS) and safety analyses of LUX-Lung 8 and investigate the characteri...

Descripción completa

Detalles Bibliográficos
Autores principales: Goss, Glenwood D, Cobo, Manuel, Lu, Shun, Syrigos, Konstantinos, Lee, Ki Hyeong, Göker, Erdem, Georgoulias, Vassilis, Isla, Dolores, Morabito, Alessandro, Min, Young J, Ardizzoni, Andrea, Bender, Shaun, Cseh, Agnieszka, Felip, Enriqueta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225678/
https://www.ncbi.nlm.nih.gov/pubmed/34195574
http://dx.doi.org/10.1016/j.eclinm.2021.100940